211 related articles for article (PubMed ID: 25696005)
21. Dialysis vintage and parathyroid hormone level, not fibroblast growth factor-23, determines chronic-phase phosphate wasting after renal transplantation.
Tomida K; Hamano T; Ichimaru N; Fujii N; Matsui I; Nonomura N; Tsubakihara Y; Rakugi H; Takahara S; Isaka Y
Bone; 2012 Oct; 51(4):729-36. PubMed ID: 22796419
[TBL] [Abstract][Full Text] [Related]
22. Fibroblast Growth Factor 23 Predicts All-Cause Mortality in a Dose-Response Fashion in Pre-Dialysis Patients with Chronic Kidney Disease.
Xue C; Yang B; Zhou C; Dai B; Liu Y; Mao Z; Yu S; Mei C
Am J Nephrol; 2017; 45(2):149-159. PubMed ID: 28006765
[TBL] [Abstract][Full Text] [Related]
23. [Correlation of fibroblast growth factor 23 with
adverse prognosis of chronic kidney disease and
therapy strategy].
Liu H; Liu H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 May; 43(5):560-565. PubMed ID: 29886473
[TBL] [Abstract][Full Text] [Related]
24. Technical and diagnostic performance of a new fully automated immunoassay for the determination of intact fibroblast growth factor 23 (FGF23).
van Helden J; Weiskirchen R
Scand J Clin Lab Invest; 2018; 78(7-8):584-590. PubMed ID: 30380963
[TBL] [Abstract][Full Text] [Related]
25. Coronary artery calcification and cardiovascular disease in children with chronic kidney disease.
Paoli S; Mitsnefes MM
Curr Opin Pediatr; 2014 Apr; 26(2):193-7. PubMed ID: 24632542
[TBL] [Abstract][Full Text] [Related]
26. Fibroblast growth factor 23 is a predictor of aortic artery calcification in maintenance hemodialysis patients.
Chen Z; Chen X; Xie J; Ma X; Zhong F; Hou L; Ling H; Li X; Ren H; Chen N
Ren Fail; 2013; 35(5):660-6. PubMed ID: 23581403
[TBL] [Abstract][Full Text] [Related]
27. Insulin resistance is associated with Fibroblast Growth Factor-23 in stage 3-5 chronic kidney disease patients.
Garland JS; Holden RM; Ross R; Adams MA; Nolan RL; Hopman WM; Morton AR
J Diabetes Complications; 2014; 28(1):61-5. PubMed ID: 24125760
[TBL] [Abstract][Full Text] [Related]
28. Uremic toxicity and sclerostin in chronic kidney disease patients.
Desjardins L; Liabeuf S; Oliveira RB; Louvet L; Kamel S; Lemke HD; Vanholder R; Choukroun G; Massy ZA;
Nephrol Ther; 2014 Nov; 10(6):463-70. PubMed ID: 25070604
[TBL] [Abstract][Full Text] [Related]
29. Associations of epicardial fat with coronary calcification, insulin resistance, inflammation, and fibroblast growth factor-23 in stage 3-5 chronic kidney disease.
Kerr JD; Holden RM; Morton AR; Nolan RL; Hopman WM; Pruss CM; Garland JS
BMC Nephrol; 2013 Jan; 14():26. PubMed ID: 23351146
[TBL] [Abstract][Full Text] [Related]
30. Relationship between serum fibroblast growth factor-23 level and mortality in chronic hemodialysis patients.
Sugimoto H; Ogawa T; Iwabuchi Y; Otsuka K; Nitta K
Int Urol Nephrol; 2014 Jan; 46(1):99-106. PubMed ID: 23355029
[TBL] [Abstract][Full Text] [Related]
31. Biological variability of plasma intact and C-terminal FGF23 measurements.
Smith ER; Cai MM; McMahon LP; Holt SG
J Clin Endocrinol Metab; 2012 Sep; 97(9):3357-65. PubMed ID: 22689697
[TBL] [Abstract][Full Text] [Related]
32. Assessment and significance of abdominal aortic calcification in chronic kidney disease.
Hanada S; Ando R; Naito S; Kobayashi N; Wakabayashi M; Hata T; Sasaki S
Nephrol Dial Transplant; 2010 Jun; 25(6):1888-95. PubMed ID: 20061316
[TBL] [Abstract][Full Text] [Related]
33. Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.
Clinkenbeard EL; Noonan ML; Thomas JC; Ni P; Hum JM; Aref M; Swallow EA; Moe SM; Allen MR; White KE
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830862
[TBL] [Abstract][Full Text] [Related]
34. Impact of serum FGF23 levels on blood pressure of patients with chronic kidney disease.
Li JX; Yu GQ; Zhuang YZ
Eur Rev Med Pharmacol Sci; 2018 Feb; 22(3):721-725. PubMed ID: 29461601
[TBL] [Abstract][Full Text] [Related]
35. Fibroblast growth factor 23/klotho axis in chronic kidney disease.
Nitta K; Nagano N; Tsuchiya K
Nephron Clin Pract; 2014; 128(1-2):1-10. PubMed ID: 25402964
[TBL] [Abstract][Full Text] [Related]
36. Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study.
Brandenburg VM; Kleber ME; Vervloet MG; Tomaschitz A; Pilz S; Stojakovic T; Delgado G; Grammer TB; Marx N; März W; Scharnagl H
Atherosclerosis; 2014 Nov; 237(1):53-9. PubMed ID: 25200615
[TBL] [Abstract][Full Text] [Related]
37. Plasmatic Klotho and FGF23 Levels as Biomarkers of CKD-Associated Cardiac Disease in Type 2 Diabetic Patients.
Silva AP; Mendes F; Carias E; Gonçalves RB; Fragoso A; Dias C; Tavares N; Café HM; Santos N; Rato F; Leão Neves P; Almeida E
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30934737
[TBL] [Abstract][Full Text] [Related]
38. FGF23 and Phosphate-Cardiovascular Toxins in CKD.
Vogt I; Haffner D; Leifheit-Nestler M
Toxins (Basel); 2019 Nov; 11(11):. PubMed ID: 31698866
[TBL] [Abstract][Full Text] [Related]
39. Method-specific differences in plasma fibroblast growth factor 23 measurement using four commercial ELISAs.
Smith ER; McMahon LP; Holt SG
Clin Chem Lab Med; 2013 Oct; 51(10):1971-81. PubMed ID: 23729624
[TBL] [Abstract][Full Text] [Related]
40. The Addition of Vascular Calcification Scores to Traditional Risk Factors Improves Cardiovascular Risk Assessment in Patients with Chronic Kidney Disease.
Liabeuf S; Desjardins L; Diouf M; Temmar M; Renard C; Choukroun G; Massy ZA
PLoS One; 2015; 10(7):e0131707. PubMed ID: 26181592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
